Skip to main content
. Author manuscript; available in PMC: 2016 Nov 7.
Published in final edited form as: Pharmacol Ther. 2013 Nov 1;141(3):283–299. doi: 10.1016/j.pharmthera.2013.10.011

Figure 4.

Figure 4

Anti-immobility effects of the NOP receptor antagonist SB-61211 in the mous forced-swim assay. TOP. Lack of effect of NOP receptor agonist RO-646198. NIH Swiss, male mice, n=4–6/group. *p<0.05 compared to vehicle (Dunnett’s test). I: Effect of 15 mg/kg imipramine. MIDDLE. Prevention of effects of SB-61211(30 mg/kg, p.o.) by RO-646198 (0.3 mg/kg). NIH Swiss male mice, n=8/group. *p<0.05 compared to vehicle (Dunnett’s test); #p<0.05 compared to 2817412 alone (t-test). Imi: imipramine (15mg/kg, i.p., n=4), 30 min prior). LOWER. RO-646198 (0.3 mg/kg, p.o.) was not effective in preventing the anti-immobility effects of imipramine (15 mg/kg, i.p.). NIH Swiss male mice, n=8/group. *p<0.05 compared to vehicle (Dunnett’s test). Behavioral methods are comparable to Li et al. (2005).